253 related articles for article (PubMed ID: 11253853)
1. The safety and antiviral effect of protease inhibitors in children.
Temple ME; Koranyi KI; Nahata MC
Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
3. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
4. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
[No Abstract] [Full Text] [Related]
5. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Lai S; Lai H; Celentano DD; Vlahov D; Ren S; Margolick J; Lima JA; Bartlett JG
AIDS Patient Care STDS; 2003 May; 17(5):211-9. PubMed ID: 12816615
[TBL] [Abstract][Full Text] [Related]
9. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.
Nadal D; Steiner F; Cheseaux JJ; Lazarevitch CA; Aebi C; Kind C; Rudin C
Infection; 2000 Sep; 28(5):287-96. PubMed ID: 11073135
[TBL] [Abstract][Full Text] [Related]
10. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
11. Effect of protease inhibitors on the sense of taste.
Schiffman SS; Zervakis J; Heffron S; Heald AE
Nutrition; 1999 Oct; 15(10):767-72. PubMed ID: 10501290
[TBL] [Abstract][Full Text] [Related]
12. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Bonfanti P; Valsecchi L; Parazzini F; Carradori S; Pusterla L; Fortuna P; Timillero L; Alessi F; Ghiselli G; Gabbuti A; Di Cintio E; Martinelli C; Faggion I; Landonio S; Quirino T
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):236-45. PubMed ID: 10839659
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
Hoffmann F; Notheis G; Wintergerst U; Eberle J; Gürtler L; Belohradsky BH
Pediatr Infect Dis J; 2000 Jan; 19(1):47-51. PubMed ID: 10643850
[TBL] [Abstract][Full Text] [Related]
14. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Chang ES; Tetreault DD; Liu YT; Beall GN
J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
[No Abstract] [Full Text] [Related]
15. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
17. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
18. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
19. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
20. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
